Viewing nowCombinationLovatitan Tablets 10/160 mg
Valsartan 160mg · Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.

MFDS item code 201309654 · Approved 2013.10.10 · Insurance code 668902640
Treatment of hypertension and heart failure; improvement of dyslipidemia; prevention of cardiovascular disease (such as arteriosclerosis)
This medication is used for patients who need to take both valsartan and rosuvastatin at the same time. Valsartan helps reduce the risk of hypertension, heart failure, and death after myocardial infarction. It is particularly effective for heart failure patients who are intolerant to ACE inhibitors, and reduces the risk of death in patients with left ventricular failure after myocardial infarction. Rosuvastatin is used to treat hypercholesterolemia and familial hypercholesterolemia, as well as mixed dyslipidemia, and serves as an adjunct when not controlled by diet and exercise. It also reduces cardiovascular disease risk and slows the progression of atherosclerosis. By using these two medications together, it is possible to improve the risks of hypertension, hyperlipidemia, and cardiovascular diseases simultaneously.
This medicine should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components, respectively. ◆ Valsartan 1. Essential hypertension Take with water during or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is required, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction in the risk of death following myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Thereafter, over the course of several weeks, the dose should be increased, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with ACE inhibitors is not recommended. 4. Patients with renal impairment: No dose adjustment is required when creatinine clearance is 10 mL/min or greater. However, because there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefit of treatment outweighs the risk when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less; however, an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Children and adolescents under 18 years of age: Safety and efficacy have not been established. Children and adolescents under 18 years of age: Safety and efficacy have not been established.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. This medication should not be used in patients with certain conditions, such as severe liver disease, renal failure, myopathy, hereditary angioedema, and others. Caution should be exercised when using this medication in the elderly, patients with hyperkalemia, and those with liver dysfunction, and regular liver function tests are recommended. Muscle-related side effects are rare but can occur, so if symptoms such as muscle pain or weakness appear, immediate consultation with a physician is necessary. Because this medication can interact with other drugs, it is essential to inform the healthcare provider of any other medications being taken. It is advisable for pregnant and breastfeeding women to avoid using this medication, and if breastfeeding, it is recommended to stop nursing. Safety for children and adolescents has not been established; therefore, use in those under 18 years should be avoided. There is no specific antidote for overdose, so immediate medical attention should be sought for appropriate treatment. This medication should be kept out of reach of children and should not be transferred to another container for safety. While taking this medication, regular checks on liver and kidney function are necessary, and if abnormal symptoms arise, immediate consultation with a healthcare provider is necessary.
Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, asthenia, chest pain, facial edema, peripheral edema, nasopharyngitis, urinary tract infection, bruises, increased serum aminotransferase levels, increased serum creatine phosphokinase, increased serum potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory disturbance, anxiety, upper respiratory infection, pharyngitis, tonsillitis, spinal stenosis, aphasia, oral bleeding, vomiting, insulin-dependent diabetes mellitus, diabetes complications, leg fracture, spinal fracture, fracture, skin mass, second-degree atrioventricular block, vestibulitis, retinal detachment, unspecified skin tumor-like condition, herpes zoster, herniated disc, hemoptysis, sputum disease, bronchitis, sensory abnormalities, hoarseness, gastroesophageal reflux, diverticulitis, stomatitis, gastritis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, elevated blood pressure, worsening hypertension, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, unspecified skin inflammation, localized skin reaction, palpitations, worsening angina, auditory disturbances, overactive bladder, increased serum creatinine, benign prostatic hyperplasia, laceration, headache, dizziness, constipation, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase increase, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory impairment, forgetfulness, amnestic syndrome, memory disorder, confusion, severe myasthenia gravis, ocular myasthenia
Not everyone experiences these, and they can vary from person to person.
This medication can be sensitive to light, so it should be stored in a container protected from light. Additionally, it is important to maintain room temperature, specifically between 1 to 30 degrees Celsius, to safely preserve the medication's efficacy.
Pink oval film-coated tablet
56 tablets (14 tablets/PTP x 4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationValsartan 160mg · Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
CombinationValsartan 160mg · Rosuvastatin Calcium Micronized 20.8mg
Tablet · Prescription medication · Combination
LG Chemical Co., Ltd.
CombinationValsartan 80mg · Rosuvastatin Calcium Micronized 20.8mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
CombinationValsartan 80mg · Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
CombinationValsartan 80mg · Rosuvastatin Calcium Micronized 5.2mg
Tablet · Prescription medication · Combination
LG Chemical Co., Ltd.
CombinationValsartan 160mg · Rosuvastatin Calcium Micronized 5.2mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.